Enovis (NYSE:ENOV) Releases FY 2026 Earnings Guidance

Enovis (NYSE:ENOV) updated its FY 2026 earnings guidance on Thursday. The company provided EPS guidance of 3.520-3.730 for the period, compared to the consensus EPS estimate of 3.350. The company issued revenue guidance of $2.3 billion-$2.4 billion, compared to the consensus revenue estimate of $2.4 billion.

Analyst Ratings Changes

ENOV has been the topic of several research reports. Canaccord Genuity Group cut their price target on Enovis from $58.00 to $50.00 and set a “buy” rating on the stock in a research note on Wednesday, December 17th. Evercore reaffirmed an “outperform” rating on shares of Enovis in a research report on Monday, January 12th. UBS Group reaffirmed a “buy” rating and set a $50.00 price target on shares of Enovis in a research report on Monday, January 5th. Wells Fargo & Company increased their price objective on shares of Enovis from $41.00 to $42.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. Finally, BTIG Research upped their price objective on Enovis from $41.00 to $43.00 and gave the stock a “buy” rating in a research report on Thursday. Seven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $47.00.

Enovis Trading Up 12.6%

NYSE:ENOV traded up $2.82 on Thursday, reaching $25.14. 1,341,209 shares of the company’s stock were exchanged, compared to its average volume of 1,121,551. The company has a quick ratio of 1.16, a current ratio of 2.22 and a debt-to-equity ratio of 0.66. Enovis has a 52-week low of $21.00 and a 52-week high of $40.69. The firm has a market capitalization of $1.44 billion, a price-to-earnings ratio of -1.05 and a beta of 1.52. The business has a fifty day moving average of $24.34 and a 200-day moving average of $28.23.

Enovis (NYSE:ENOV) last released its quarterly earnings data on Thursday, February 26th. The company reported $0.95 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.81 by $0.14. Enovis had a negative net margin of 61.22% and a positive return on equity of 7.79%. The business had revenue of $575.76 million during the quarter, compared to analysts’ expectations of $584.30 million. During the same period in the previous year, the company earned $0.98 EPS. The company’s revenue for the quarter was up 2.6% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, analysts expect that Enovis will post 2.79 earnings per share for the current year.

Insider Activity

In related news, EVP Daniel A. Pryor sold 999 shares of the stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $27.20, for a total value of $27,172.80. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 2.70% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. FORA Capital LLC acquired a new position in Enovis in the second quarter worth $304,000. Mackenzie Financial Corp grew its holdings in Enovis by 31.3% during the 3rd quarter. Mackenzie Financial Corp now owns 9,555 shares of the company’s stock worth $290,000 after acquiring an additional 2,275 shares during the period. Gabelli Funds LLC bought a new position in Enovis during the second quarter worth about $289,000. Creative Planning bought a new stake in Enovis in the third quarter valued at approximately $274,000. Finally, Empowered Funds LLC raised its stake in Enovis by 13.0% during the 1st quarter. Empowered Funds LLC now owns 6,515 shares of the company’s stock worth $249,000 after buying an additional 749 shares during the period. Institutional investors and hedge funds own 98.45% of the company’s stock.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.